Member Info for neilrich3

....and in other news Sainsbury's a target for a take over. Don't suppose the Czech Billionaire is in to diagnostics. https://www.telegraph.co.uk/business/2021/04/13/czech-billionaire-swoops-sainsburys/

Surly if it was Novacyt Group providing the surge testing they'd be more direct and state that we're proud to be delivering variplex to the British government, although can't be much in the way of money. Despite 700,000 PCR it would only be the one variplex for each positive test.

Also, more than happy to spend £50 plus in the airport bar, but can't understand why they should pay for a covid test.

PCR testing is to become an important revenue stream for airports, unfortunately all airports are looking to take their cut. Traditionally smaller regional airports would make most of their money from car parking and retail (duty free), passenger numbers shall be a fraction of what they once were. My thinking is that with airport PCR tests typically priced at £90-110, the airports shall be taking a 30% cut, therefore a potentially massive and very important stream of revenue. Airports are on their knees write now, including Heathrow and Gatwick. Heathrow loosing more than £1billion a year. None of these companies shall be prepared to subsidise and offer testing at a loss.

FLASH - A new variant of # COVID19 has been detected in northern Rio de Janeiro. “The strain has a combination of 18 mutations that have never been found together,” explains a Brazilian newspaper. (The Express)

Have already been selling our tests to DHSC for less than £10 and to commercial/private healthcare for less than £15. With regards to Versalab, I'd imagine that our overheads are relatively low when compared to a clinical lab and therefore NCYT are well placed to offer retail PCR tests at a very competitive price.

Diagnostics are set to revolutionise health care, so much more than just testing for Covid.

Testing shall remain in place for at least the next decade, vaccination is not the silver bullet that the Government would have you believe. Check the Surge Testing in London Today, many of those testing positive for the SA variant have previously received the vaccine.

From the Telegraph...It is thought the virus was spread from that individual to members of their household and then to a care home in Lambeth where 13 staff and 10 residents were infected. Six of the 10 residents had received one dose of the AstraZeneca vaccine two or more weeks before their positive test date. One of the 13 infected staff had a single Pfizer vaccine dose two or more weeks before their positive test.

What would be a 'ludicrously high price' ?

You'd not expect a potential suitor to be pay anything less than x5 earnings, which happens to be North of £15 in the case of NCYT, that's not a high price.

https://twitter.com/BlackbirdInvest/status/1382009791472672768

The most interesting news Today was the results from SourceBioScience and the comparison with Novacyt.

NCYT: Market Cap £300m Revenue £277m EBITDA £187m CASH £130M (estimate) PE <2
SBI: Market Cap £150m Revenue £50m EBITDA £14.2M CASH £8.4M. PE 10

Should the market value NCYT at the same multiple as SBI the NCYT share price would be >£20.00. That's a rough calculation and does not take into account our cash position.

What is going on?

121,700 @ 437p has to be a buy.

Precisely why Nick Plummer has been brought onboard...to look after the legal side.

Before Friday's RNS I'd have said yes, however now I'm not so sure. There are other companies offering similar tests for variants.

https://twitter.com/glr_1990/status/1381886109840506880

https://twitter.com/TaylorQuant/status/1381867282226409472

...and their shares up more than 10% at the open.

Sourcebio have just released their full year results, EPS 19.8p and therefore trading at x10 earnings. Very similar business to Novacyt....what's going on?!

Nick Plummer is from Thermo Fisher.....not Abbott

https://salient.bio/

Anybody know whether they are using Primerdesign?

Senior Territory Account Manager

The above roles are focused upon selling to the NHS and are still being advertised.

Not using the products and wish to return them....why would they spend £36 million outside of contract on PROmate.